Veracyte Inc. | C2I Genomics

Veracyte Inc. | C2I Genomics company information, Employees & Contact Information

C2i Genomics is now part of Veracyte. We encourage you to follow Veracyte on LinkedIn at: https://www.linkedin.com/company/veracyte/.

Company Details

Employees
21
Address
New York, Ny, Us
Email
in****@****ics.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
New York, NY
Looking for a particular Veracyte Inc. | C2I Genomics employee's phone or email?

Veracyte Inc. | C2i Genomics Questions

News

How C2i Genomics builds on AWS to transform cancer care - Amazon Web Services

How C2i Genomics builds on AWS to transform cancer care Amazon Web Services

JPM24: Veracyte inks $95M deal to buy fellow cancer testing company C2i Genomics - Fierce Biotech

JPM24: Veracyte inks $95M deal to buy fellow cancer testing company C2i Genomics Fierce Biotech

C2i Genomics Partners with Twist Bioscience to Launch Reference Materials for Whole-Genome Cancer Detection - Business Wire

C2i Genomics Partners with Twist Bioscience to Launch Reference Materials for Whole-Genome Cancer Detection Business Wire

Cancer care startup C2i Genomics acquired by Veracyte for up to $95 million - CTech

Cancer care startup C2i Genomics acquired by Veracyte for up to $95 million CTech

Regina Nagle appointed as SVP of Business Development at C2i Genomics – Asaf Zviran - Oncodaily

Regina Nagle appointed as SVP of Business Development at C2i Genomics – Asaf Zviran Oncodaily

Veracyte Adds AI-Driven MRD Testing Capabilities with C2i Genomics Acquisition - Inside Precision Medicine

Veracyte Adds AI-Driven MRD Testing Capabilities with C2i Genomics Acquisition Inside Precision Medicine

A sensitive strategy for tumour surveillance - Nature

A sensitive strategy for tumour surveillance Nature

Peninsula cancer test developer to pay $70 million upfront for Israeli company - The Business Journals

Peninsula cancer test developer to pay $70 million upfront for Israeli company The Business Journals

Veracyte acquires C2i Genomics for $95m to boost cancer diagnostics range - Medical Device Network

Veracyte acquires C2i Genomics for $95m to boost cancer diagnostics range Medical Device Network

Why NFX Invested In C2i Genomics: The Cancer Surveillance Platform - NFX

Why NFX Invested In C2i Genomics: The Cancer Surveillance Platform NFX

AstraZeneca extends C2i pact to validate minimal residual disease solid tumor blood test - MedTech Dive

AstraZeneca extends C2i pact to validate minimal residual disease solid tumor blood test MedTech Dive

C2i Genomics, Karkinos Healthcare partner to bring AI-powered cancer R&D to India - The Cancer Letter

C2i Genomics, Karkinos Healthcare partner to bring AI-powered cancer R&D to India The Cancer Letter

C2i Genomics: Building A Comprehensive Whole-Genome Cancer Monitoring Platform - Pulse 2.0

C2i Genomics: Building A Comprehensive Whole-Genome Cancer Monitoring Platform Pulse 2.0

Veracyte Acquires C2i Genomics for $70M, Expanding into Minimal Residual Disease Detection - HIT Consultant

Veracyte Acquires C2i Genomics for $70M, Expanding into Minimal Residual Disease Detection HIT Consultant

ASCO: C2i Genomics CEO, CTO aim to create a 'one-stop shop for precision oncology' - Fierce Biotech

ASCO: C2i Genomics CEO, CTO aim to create a 'one-stop shop for precision oncology' Fierce Biotech

The Care Continuum: Veracyte’s CEO on its Diagnostic Strategy - CMC Markets

The Care Continuum: Veracyte’s CEO on its Diagnostic Strategy CMC Markets

C2i Genomics introduces minimal residual disease test for cancer in Europe - Medical Device Network

C2i Genomics introduces minimal residual disease test for cancer in Europe Medical Device Network

Paz Polak: In a correspondence letter we wrote for the NEJM, we suggested that testing for POLE, and even better, checking for POLE-associated mutational signatures - Oncodaily

Paz Polak: In a correspondence letter we wrote for the NEJM, we suggested that testing for POLE, and even better, checking for POLE-associated mutational signatures Oncodaily

C2i Genomics lands $100M to scale up software that detects tiny traces of cancer in a single blood draw - Fierce Biotech

C2i Genomics lands $100M to scale up software that detects tiny traces of cancer in a single blood draw Fierce Biotech

C2i Genomics snags European approval for blood test to detect residual cancer - Fierce Biotech

C2i Genomics snags European approval for blood test to detect residual cancer Fierce Biotech

A blood test that can identify recurrent cancer - Unpacked

A blood test that can identify recurrent cancer Unpacked

AI cancer startup collaborates with top Israeli hospital - Unpacked

AI cancer startup collaborates with top Israeli hospital Unpacked

Veracyte to buy Israeli cancer detection co C2i Genomics - גלובס

Veracyte to buy Israeli cancer detection co C2i Genomics גלובס

8 Whole Genome Sequencing Companies for Precision Health - Nanalyze

8 Whole Genome Sequencing Companies for Precision Health Nanalyze

Omri Drory, Ph.D. - NFX

Omri Drory, Ph.D. NFX

Top Veracyte Inc. | C2I Genomics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant